Enfermedad renal crónica y transplante
ERYTRA
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Navarra (10)
2022
-
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
2021
-
Small molecule-based enzyme inhibitors in the treatment of primary hyperoxalurias
Journal of Personalized Medicine, Vol. 11, Núm. 2, pp. 1-31
2019
2018
-
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I
Nature Communications, Vol. 9, Núm. 1
2016
-
Generation and characterization of human iPSC lines derived from a Primary Hyperoxaluria Type I patient with p.I244T mutation
Stem Cell Research, Vol. 16, Núm. 1, pp. 116-119
2013
2006
-
Increased cardiovascular risk profile and mortality in kidney allograft recipients with post-transplant diabetes mellitus in Spain
Clinical Transplantation, Vol. 20, Núm. 5, pp. 650-658
2003
-
High prevalence of overweight in a stable spanish hemodialysis population: A cross sectional study
Journal of Renal Nutrition, Vol. 13, Núm. 1, pp. 52-59
2001
-
Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients
American Journal of Kidney Diseases, Vol. 37, Núm. 6, pp. 1260-1266